Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1988 Apr;56(4):843–848. doi: 10.1128/iai.56.4.843-848.1988

Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice.

D Frommel 1, B W Ogunkolade 1, I Vouldoukis 1, L Monjour 1
PMCID: PMC259379  PMID: 3346074

Abstract

Partially purified antigens, derived from Leishmania infantum or L. major promastigotes and isolated under reducing conditions, were used to immunize BALB/c mice. Three subcutaneous injections of the 64- to 97-kilodalton preparation in conjunction with muramyl dipeptide conferred long-lasting immunity against L. mexicana subsp. mexicana and L. major infection; they led to the development of antibodies neutralizing the infectiousness of promastigotes, induced specific delayed-hypersensitivity reactions, and generated populations of peritoneal macrophages capable of killing amastigotes. Vaccination resulted in no harmful effects, since these antigen neither exacerbated preexisting Leishmania infection nor impeded the formation of antibodies to other antigens administered concomitantly.

Full text

PDF
845

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson S., David J. R., McMahon-Pratt D. In vivo protection against Leishmania mexicana mediated by monoclonal antibodies. J Immunol. 1983 Oct;131(4):1616–1618. [PubMed] [Google Scholar]
  2. Antunes C. M., Mayrink W., Magalhaes P. A., Costa C. A., Melo M. N., Dias M., Michalick M. S., Williams P., Lima A. O., Vieira J. B. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol. 1986 Dec;15(4):572–580. doi: 10.1093/ije/15.4.572. [DOI] [PubMed] [Google Scholar]
  3. Barral-Netto M., Reed S. G., Sadigursky M., Sonnenfeld G. Specific immunization of mice against Leishmania mexicana amazonensis using solubilized promastigotes. Clin Exp Immunol. 1987 Jan;67(1):11–19. [PMC free article] [PubMed] [Google Scholar]
  4. Buchmüller Y., Mauel J. Studies on the mechanisms of macrophage activation. II. Parasite destruction in macrophages activated by supernates from concanavalin A-stimulated lymphocytes. J Exp Med. 1979 Aug 1;150(2):359–370. doi: 10.1084/jem.150.2.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chang C. S., Chang K. P. Monoclonal antibody affinity purification of a Leishmania membrane glycoprotein and its inhibition of leishmania-macrophage binding. Proc Natl Acad Sci U S A. 1986 Jan;83(1):100–104. doi: 10.1073/pnas.83.1.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Colomer-Gould V., Glvao Quintao L., Keithly J., Nogueira N. A common major surface antigen on amastigotes and promastigotes of Leishmania species. J Exp Med. 1985 Sep 1;162(3):902–916. doi: 10.1084/jem.162.3.902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Debons-Guillemin M. C., Vouldoukis I., Roseto A., Alfred C., Chopin C., Ploton I., Monjour L. Inhibition in vivo of both infective Leishmania major and L. mexicana amazonensis mediated by a single monoclonal antibody. Trans R Soc Trop Med Hyg. 1986;80(2):258–260. doi: 10.1016/0035-9203(86)90030-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Etges R., Bouvier J., Bordier C. The major surface protein of Leishmania promastigotes is a protease. J Biol Chem. 1986 Jul 15;261(20):9098–9101. [PubMed] [Google Scholar]
  9. Greenblatt C. L. The present and future of vaccination for cutaneous leishmaniasis. Prog Clin Biol Res. 1980;47:259–285. [PubMed] [Google Scholar]
  10. Handman E., Hocking R. E. Stage-specific, strain-specific, and cross-reactive antigens of Leishmania species identified by monoclonal antibodies. Infect Immun. 1982 Jul;37(1):28–33. doi: 10.1128/iai.37.1.28-33.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Handman E., Mitchell G. F. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5910–5914. doi: 10.1073/pnas.82.17.5910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Howard J. G. Immunological regulation and control of experimental leishmaniasis. Int Rev Exp Pathol. 1986;28:79–116. [PubMed] [Google Scholar]
  13. Howard J. G., Liew F. Y., Hale C., Nicklin S. Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes. J Immunol. 1984 Jan;132(1):450–455. [PubMed] [Google Scholar]
  14. Howard J. G., Nicklin S., Hale C., Liew F. Y. Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J Immunol. 1982 Nov;129(5):2206–2212. [PubMed] [Google Scholar]
  15. Jones T. C., Len L., Hirsch J. G. Assessment in vitro of immunity against Toxoplasma gondii. J Exp Med. 1975 Feb 1;141(2):466–482. doi: 10.1084/jem.141.2.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  17. Liew F. Y., Hale C., Howard J. G. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J Immunol. 1985 Sep;135(3):2095–2101. [PubMed] [Google Scholar]
  18. Liew F. Y., Singleton A., Cillari E., Howard J. G. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection. J Immunol. 1985 Sep;135(3):2102–2107. [PubMed] [Google Scholar]
  19. Mitchell G. F., Handman E. Leishmania tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility. Aust J Exp Biol Med Sci. 1983 Feb;61(Pt 1):11–25. doi: 10.1038/icb.1983.2. [DOI] [PubMed] [Google Scholar]
  20. Mitchell G. F., Handman E., Spithill T. W. Examination of variables in the vaccination of mice against cutaneous leishmaniasis using living avirulent cloned lines and killed promastigotes of Leishmania major. Int J Parasitol. 1985 Dec;15(6):677–684. doi: 10.1016/0020-7519(85)90015-3. [DOI] [PubMed] [Google Scholar]
  21. Monjour L., Berneman A., Vouldoukis I., Domurado M., Guillemin M. C., Chopin C., Alfred C., Roseto A. Des anticorps monoclonaux contre des antigènes définis de Leishmania protègent la Souris contre l'infection par différentes espèces de Leishmania. C R Acad Sci III. 1985;300(9):395–398. [PubMed] [Google Scholar]
  22. Monjour L., Vouldoukis I., Brandicourt O., Mazier D., Alfred C., Ploton I., Gentilini M. Rapid, large-scale production and isolation for Leishmania amastigotes. Ann Trop Med Parasitol. 1984 Aug;78(4):423–425. doi: 10.1080/00034983.1984.11811840. [DOI] [PubMed] [Google Scholar]
  23. Nacy C. A., Meltzer M. S., Leonard E. J., Wyler D. J. Intracellular replication and lymphokine-induced destruction of Leishmania tropica in C3H/HeN mouse macrophages. J Immunol. 1981 Dec;127(6):2381–2386. [PubMed] [Google Scholar]
  24. O'Daly J. A., Cabrera Z. Immunization of hamsters with TLCK-killed parasites induces protection against Leishmania infection. Acta Trop. 1986 Sep;43(3):225–236. [PubMed] [Google Scholar]
  25. Oster C. N., Nacy C. A. Macrophage activation to kill Leishmania tropica: kinetics of macrophage response to lymphokines that induce antimicrobial activities against amastigotes. J Immunol. 1984 Mar;132(3):1494–1500. [PubMed] [Google Scholar]
  26. Preston P. M., Dumonde D. C. Experimental cutaneous leishmaniasis. V. Protective immunity in subclinical and self-healing infection in the mouse. Clin Exp Immunol. 1976 Jan;23(1):126–138. [PMC free article] [PubMed] [Google Scholar]
  27. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol. 1987 Jul 1;139(1):221–227. [PubMed] [Google Scholar]
  28. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract. J Immunol. 1987 Nov 1;139(9):3118–3125. [PubMed] [Google Scholar]
  29. Steinberger A., Slutzky G. M., El-On J., Greenblatt C. L. Leishmania tropica: protective response in C3H mice vaccinated with excreted factor crosslinked with the synthetic adjuvant, muramyl dipeptide. Exp Parasitol. 1984 Dec;58(3):223–229. doi: 10.1016/0014-4894(84)90038-9. [DOI] [PubMed] [Google Scholar]
  30. Titus R. G., Lima G. C., Engers H. D., Louis J. A. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity. J Immunol. 1984 Sep;133(3):1594–1600. [PubMed] [Google Scholar]
  31. Warren H. S., Vogel F. R., Chedid L. A. Current status of immunological adjuvants. Annu Rev Immunol. 1986;4:369–388. doi: 10.1146/annurev.iy.04.040186.002101. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES